IRIS
BIANCO, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 8.084
NA - Nord America 7.078
EU - Europa 6.109
SA - Sud America 851
Continente sconosciuto - Info sul continente non disponibili 320
AF - Africa 211
OC - Oceania 15
Totale 22.668
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.774
SG - Singapore 3.427
RU - Federazione Russa 2.517
IT - Italia 1.607
VN - Vietnam 1.599
CN - Cina 1.558
BR - Brasile 678
HK - Hong Kong 565
DE - Germania 427
FR - Francia 291
UA - Ucraina 240
FI - Finlandia 230
NL - Olanda 227
CA - Canada 195
BD - Bangladesh 180
IN - India 175
GB - Regno Unito 149
IE - Irlanda 144
JP - Giappone 134
CI - Costa d'Avorio 79
SE - Svezia 78
AR - Argentina 71
KR - Corea 71
PL - Polonia 54
MX - Messico 51
ZA - Sudafrica 49
PK - Pakistan 48
PH - Filippine 47
TH - Thailandia 36
IQ - Iraq 35
ID - Indonesia 33
ES - Italia 30
EC - Ecuador 26
TR - Turchia 25
BE - Belgio 23
VE - Venezuela 21
UZ - Uzbekistan 20
EG - Egitto 19
MY - Malesia 18
CO - Colombia 17
AT - Austria 15
MA - Marocco 15
SA - Arabia Saudita 13
TW - Taiwan 13
LT - Lituania 12
PY - Paraguay 12
TN - Tunisia 11
IL - Israele 10
JM - Giamaica 10
AU - Australia 9
CL - Cile 9
AE - Emirati Arabi Uniti 8
JO - Giordania 8
NP - Nepal 8
PE - Perù 8
TT - Trinidad e Tobago 8
BG - Bulgaria 7
ET - Etiopia 7
HN - Honduras 7
IR - Iran 7
AZ - Azerbaigian 6
CR - Costa Rica 6
DZ - Algeria 6
LB - Libano 6
NI - Nicaragua 6
RS - Serbia 6
SK - Slovacchia (Repubblica Slovacca) 6
BO - Bolivia 5
CZ - Repubblica Ceca 5
GR - Grecia 5
KE - Kenya 5
PT - Portogallo 5
SV - El Salvador 5
AL - Albania 4
BB - Barbados 4
KH - Cambogia 4
KZ - Kazakistan 4
RO - Romania 4
SI - Slovenia 4
XK - ???statistics.table.value.countryCode.XK??? 4
AO - Angola 3
BS - Bahamas 3
CH - Svizzera 3
CY - Cipro 3
DK - Danimarca 3
KW - Kuwait 3
NZ - Nuova Zelanda 3
OM - Oman 3
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
CG - Congo 2
DO - Repubblica Dominicana 2
EE - Estonia 2
GE - Georgia 2
GT - Guatemala 2
GY - Guiana 2
KG - Kirghizistan 2
LK - Sri Lanka 2
MK - Macedonia 2
MN - Mongolia 2
Totale 22.313
Salva come PNG Salva come JPEG
Città #
Singapore 1.656
San Jose 1.085
Moscow 641
Ashburn 602
Hong Kong 542
Chandler 524
Beijing 480
Ho Chi Minh City 458
Naples 388
Hanoi 357
Hefei 311
Santa Clara 265
Jacksonville 238
The Dalles 208
Dallas 200
Amsterdam 190
Napoli 189
Los Angeles 179
Lauterbourg 167
Munich 160
Millbury 156
New York 131
Princeton 116
Tokyo 104
Buffalo 89
Boston 88
São Paulo 80
Chicago 76
Nanjing 75
Rome 73
Haiphong 71
Council Bluffs 67
Da Nang 65
Redondo Beach 64
Turku 61
Wilmington 61
Ottawa 57
Woodbridge 54
Houston 52
Seoul 52
Orem 49
Des Moines 46
Milan 46
Kochi 45
Montreal 43
Toronto 43
Frankfurt am Main 42
Brooklyn 41
Helsinki 40
Seattle 39
London 38
Nanchang 36
Warsaw 36
Biên Hòa 30
Denver 28
Dong Ket 28
Pune 28
Stockholm 28
Mexico City 27
Falkenstein 26
Hebei 25
Hải Dương 25
Phoenix 25
Atlanta 24
Caserta 24
Nuremberg 24
Boardman 23
Hicksville 23
Shenyang 23
Johannesburg 21
Lawrence 21
Chennai 20
Norwalk 20
Tianjin 20
Changsha 19
Ann Arbor 18
Tashkent 18
Can Tho 17
Rio de Janeiro 17
Belo Horizonte 16
San Francisco 16
Baghdad 15
Islamabad 15
Jiaxing 15
Lahore 15
Ninh Bình 15
Quận Ba 15
Salt Lake City 15
Shanghai 15
Turin 15
Brussels 14
Kronberg 14
Porto Alegre 14
Redwood City 14
Charlotte 13
Guangzhou 13
Washington 13
Dublin 12
Formia 12
Manchester 12
Totale 11.876
Salva come PNG Salva come JPEG
Nome #
null 223
Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors 216
Development of 1,2,3-Triazole-Based Sphingosine Kinase Inhibitors and Their Evaluation as Antiproliferative Agents 214
Impaired Seroconversion After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccine in Patients With Thymic Epithelial Tumors 202
The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity 190
Epigenetic silencing of THY1 tracks the acquisition of the Notch1-EGFR signaling in a xenograft model of CD44+/CD24low/CD90+ myoepithelial cells 181
Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors 169
DLL3 as a potential diagnostic and therapeutic target in neuroendocrine neoplasms: A narrative review 169
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer 168
Everolimus induces Met inactivation by disrupting the FKBP12/Met complex 168
1599P - Effects of Hedgehog signaling inhibition on epithelial-stromal interactions in triple negative breast cancer cells 166
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status 166
Evaluation of exercise capacity by means of cardiopulmonary exercise testing (CPET) in older adult cancer patients undergoing antineoplastic treatments 164
C-Src and EGFR inhibition in molecular cancer therapy: What else can we improve? 162
Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. 161
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 161
NTRK Fusions, from the Diagnostic Algorithm to Innovative Treatment in the Era of Precision Medicine 160
Tumour microenvironment and immune evasion in EGFR addicted NSCLC: Hurdles and possibilities 160
Addition of erlotinib to fluoropyrimidine-oxaliplatin-basedchemotherapy with or without bevacizumab: Two sequential phase I trials 158
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 156
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 156
Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis. 155
Studio dei meccanismi autocrini e paracrini di attivazione di Hedgehog in modelli tumorali umani. 154
Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to anti-epidermal growth factor receptor antibody 154
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 154
Use of folfirinox or nab-paclitaxel plus gemcitabine for the treatment of locally advanced pancreatic adenocarcinoma: A single institution observational study 154
Prevention of cardiovascular complications in elderly cancer patients 153
Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling. 152
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era 152
Mechanisms of resistance to mTOR inhibitors 149
Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy 148
Liposomal Doxorubicin, Vinblastine and Dacarbazine Plus Consolidation Radiotherapy of Residual Nodal Masses for Frontline Treatment in Older Adults With Advanced Stage Classic Hodgkin Lymphoma: Improved Outcome in a Multi-Center Real-Life Study 148
The Impact of Translational Research in Breast Cancer Care: Can We Improve the Therapeutic Scenario? 148
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study 147
Role of sphingosine kinase 1 (SphK1) on cetuximab resistance in colorectal cancer models 147
Mechanisms of lapatinib resistance in HER2-driven breast cancer 147
Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer 146
Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials 146
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. 145
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer 145
AXL is an oncotarget in human colorectal cancer 143
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 142
RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges 142
Paraneoplastic sensitive neuropathy associated with anti-hu antibodies in a neuroendocrine tumor of duodenum: a case report. 142
COVID-19 in patients with thymic epithelial tumors with or without Good's syndrome: a single-center retrospective study 141
Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: a systematic review 141
Antitumor activity of combined treatment of human cancer cells with ionizing radiations and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. 140
SPHINGOSINE KINASE 1 (SPHK1) CONTRIBUTES TO RESISTANCE TO EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS IN COLORECTAL CANCER MODELS 140
KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies 139
Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. 139
P0081 Src inhibitors act through different mechanisms to cooperate with EGFR or MEK inhibitors in NSCLC models sensitive or resistant to erlotinib 139
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers 139
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges 137
Exploring the interplay between Kaposi's sarcoma and SARS‐CoV‐2 infection: A case series and systematic review 136
Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: tolerability, and prognostic factors. 136
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. 135
Approaches for targeting cancer stem cells drug resistance 135
Combined blockade of mTOR and p21-activated kinases pathways prevents tumour growth in KRAS-mutated colorectal cancer 134
Predictors of outcomes in patients with EGFR-mutated non-small cell lung cancer receiving EGFR tyrosine kinase inhibitors: A systematic review and meta-analysis 134
Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment 133
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells 133
Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models 133
Checkpoint based immunotherapy in non-small cell lung cancer: a real-world retrospective study 132
Enzastaurin inhibits tumors sensitive and resistant to anti-EGFR drugs 132
How can we manage the cardiac toxicity of immune checkpoint inhibitors? 132
Inhibition of growth factors production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. 131
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. 131
Epidermal growth factor receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models. 131
Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients 130
RET Inhibitors in Non-Small-Cell Lung Cancer 130
FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study 129
High-rsolution melting analysis (HRMA) for KRAS mutatiinal study in patients with metastatic colorectal cancer (mCRC pts) 128
EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer 127
The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer 127
Antiangiogenic and antitumor activity of anti-EGFR C225 monoclonal antibody in combination with Vascular Endothelial Growth Factor antisense oligonucleotide in human GEO colon cancer cells. 127
Preliminary analysis of chemotheraphy-induced cardiotoxicity in breast cancer patients trated with Amifostine. 126
The Epithelial-Stromal Interaction as a Potential Target for Breast Cancer Treatment 126
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents 126
Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe 126
Blinded independent central review versus local investigator assessment of PFS in RCTs of immunotherapy in advanced cancers: A systematic review and meta-analysis 126
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part 125
A phase II study of beweekly oxaliplatin plus infusional 5fluorouracil and folinic acid (FOLFOX4) as first-line treatment of advenced gastric cancer patients 125
Health-related quality of life is underestimated and underreported in phase III clinical trials in NSCLC 124
Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. 124
Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells 123
COMBINED TARGETING OF EGFR AND MDM2 BY GEFITINIB AND ANTISENSE MDM2 COOPERATIVELY INHIBIT HORMONE-INDEPENDENT PROSTATE CANCER. 122
From biology to therapy: Improvements of therapeutic options in Lung cancer 122
Core curriculum. Oncologia clinica 121
Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma. 120
Molecular heterogeneity in lung cancer: From mechanisms of origin to clinical implications 120
Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma 119
A Novel Toll-Like Receptor 9 Agonist Cooperates with Trastuzumab in Trastuzumab-Resistant Breast Tumors through Multiple Mechanisms of Action 119
Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: A case report 119
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies 118
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an EGFR-selective tyrosine kinase inhibitor. 118
The mechanisms of resistance to EGFR inhibitors. 118
RNA-Based Next-Generation Sequencing in Non-Small Cell Lung Cancer patients: data from Campania, Italy 117
Case report: Potential role of immunotherapy in thymic malignancies: a unique case of a durable and complete response upon an immune checkpoint inhibitor 116
Combination of biological therapies in non-small cell lung cancer. 116
Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A. 115
Totale 14.265
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.619
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.619
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022863 0 1 11 25 12 25 11 29 156 73 206 314
2022/20231.367 152 110 48 102 146 163 8 129 207 197 64 41
2023/20241.000 35 140 138 100 45 106 25 118 20 21 194 58
2024/20255.494 236 258 15 99 165 279 575 372 336 600 2.117 442
2025/202611.270 1.179 794 1.238 976 1.837 498 1.280 573 1.381 736 365 413
2026/2027442 273 169 0 0 0 0 0 0 0 0 0 0
Totale 22.668